Start CBT-I and Sleep Medication Together for Insomnia

Strong Evidence Supports Starting Sleep Therapy and Medication Together for Chronic Insomnia

A task force from the American Academy of Sleep Medicine (AASM) now suggests that for adults with chronic insomnia, starting cognitive behavioral therapy for insomnia (CBT-I) concurrently with sleep medication is a more effective approach than using medication alone. The “conditional” recommendation, published in the Journal of Clinical Sleep Medicine in April 2026, is based on a systematic review led by Daniel J. Buysse, MD, of the University of Pittsburgh. It marks a shift in standard clinical practice, moving beyond the question of which treatment to use first and toward a model of integrated care. This guideline establishes combination treatment, defined as CBT-I and pharmacotherapy initiated together, as a valid and often preferable strategy for managing a disorder that affects an estimated 10% of adults.

Understanding the Combination: CBT-I and Medication Defined

Combination treatment is not a haphazard mix of pills and therapy. It is a deliberate, concurrent initiation of two evidence-based interventions, each with a distinct role.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is a multicomponent, skills-based psychotherapy considered the first-line treatment for chronic insomnia. It addresses the thoughts and behaviors that perpetuate sleep problems over time. Core components include stimulus control (reassociating the bed with sleep), sleep restriction (temporarily limiting time in bed to consolidate sleep), cognitive therapy (changing unhelpful beliefs about sleep), and sleep hygiene education. Unlike medication, CBT-I aims to produce lasting improvements by teaching patients to become their own sleep experts. Its effects are durable, often persisting for years after treatment ends, as supported by long-term studies including a four-year follow-up of CBT-I success.

Pharmacotherapy for Insomnia

Insomnia medications include FDA-approved drugs such as benzodiazepine receptor agonists (e.g., zolpidem, eszopiclone), dual orexin receptor antagonists (e.g., suvorexant, lemborexant), melatonin receptor agonists (ramelteon), and others used off-label, like certain sedating antidepressants. Their primary role is to provide symptomatic relief by reducing sleep onset latency or increasing total sleep time in the short to medium term. However, questions remain about long-term efficacy, potential for side effects or tolerance, and the fact that benefits often diminish when the drug is discontinued.

The Rationale for a Combined First Strike

The 2026 AASM guideline rationale hinges on the complementary strengths and weaknesses of each monotherapy. Medication can offer rapid relief, breaking the cycle of sleeplessness and frustration. This quick win may improve a patient’s engagement and belief in the therapeutic process of CBT-I. Simultaneously, CBT-I begins the work of addressing the underlying psychological and behavioral drivers of insomnia. As patients learn and practice CBT-I skills, the need for medication often decreases, potentially allowing for a smoother, more guided taper. The combination, therefore, targets both immediate symptoms and long-term causes.

The task force’s systematic review found that combined treatment generally leads to greater improvements in sleep measures—such as how long it takes to fall asleep and how long sleep lasts—compared to pharmacotherapy alone. The evidence also indicated that combination treatment is about as effective as CBT-I alone, but may offer faster initial symptom reduction.

How the AASM Reached Its Conditional Recommendation

The guideline development process was rigorous. The AASM commissioned a panel of sleep experts who conducted a systematic review of the literature, assessing the quality of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. They considered four factors: the certainty of the evidence, the balance of benefits and harms, patient values and preferences, and resource use.

Evidence Certainty and Benefit Balance

The panel judged the certainty of evidence comparing combination therapy to medication alone as “low.” This reflects the limited number of high-quality randomized controlled trials on this specific timing of interventions. Despite the low certainty, the consistent direction of effect—favoring combination therapy—and the low risk of added harm from supervised CBT-I led the panel to make a suggestion in its favor. The potential upside of better, more durable outcomes outweighed the minimal downside of engaging in therapy.

Patient Preferences Are Central to the Choice

The “conditional” strength of the recommendation is critical. It is not a mandate. Instead, it requires clinicians to engage in detailed shared decision-making with each patient. Some patients have a strong aversion to medication; others may be skeptical of therapy’s effectiveness. The clinician’s role is to explain the evidence, outline the pros and cons of each option (CBT-I alone, medication alone, or combination), and incorporate the patient’s personal priorities and concerns. A patient seeking the fastest possible relief may value the combined approach, while one focused solely on non-drug solutions may opt for CBT-I monotherapy.

Implementing Combination Treatment in Practice

Effective combination therapy is more than just a prescription and a therapy workbook. It requires coordination and clear communication.

The Ideal Clinical Pathway

Following a comprehensive sleep evaluation to confirm chronic insomnia disorder, a clinician—often a sleep physician, psychiatrist, or primary care provider working with a behavioral sleep specialist—would discuss the treatment options. If the patient agrees to combination therapy, they would start a medication at an appropriate dose and schedule their first CBT-I session concurrently. CBT-I is typically delivered over 6-8 sessions. Throughout this period, the prescribing clinician monitors medication effects and side effects, while the therapist guides the behavioral and cognitive work. As sleep improves and CBT-I skills solidify, a plan to taper the medication is developed collaboratively, often before the end of the therapy program. This structured approach is detailed in resources like the CBT-I and sleep medication combined therapy guide.

Addressing Common Barriers and Limitations

Access remains a significant hurdle. There is a shortage of trained CBT-I providers, and insurance coverage can be inconsistent. However, the landscape is improving with the advent of validated digital CBT-I programs and apps, which can increase access and may be used in a combined approach. Another limitation is that the evidence base, while growing, still lacks large-scale studies defining the optimal medication class for combination or the ideal tapering schedule. Furthermore, as research noted in the study on depression predicting CBT-I outcomes shows, co-existing conditions like depression can influence results and must be managed concurrently.

The Future of Insomnia Treatment Is Integrated

The 2026 AASM guideline on combination treatment represents a maturation in sleep medicine. It moves the field away from simplistic either/or debates and toward a more nuanced, personalized model of care. By acknowledging that the concurrent use of biological and behavioral tools can be optimal, it empowers clinicians and patients with more strategies. The ultimate goal is not merely to induce sleep tonight, but to build the skills for restorative sleep every night, long after treatment ends. This approach aligns with the broader shift in healthcare toward integrated care models that address the full complexity of chronic conditions.

Key Takeaways

• A 2026 American Academy of Sleep Medicine guideline suggests that for adults with chronic insomnia, starting CBT-I and sleep medication together is more effective than using medication alone.
• Combination treatment uses medication for faster symptom relief while CBT-I works concurrently to address the underlying causes of insomnia for lasting change.
• The recommendation is “conditional,” meaning it requires shared decision-making between clinician and patient, heavily weighing personal preferences and values.
• Successful implementation involves coordinated care, with medication management and therapy happening in parallel, followed by a planned medication taper.
• While access to CBT-I can be a barrier, digital CBT-I platforms are emerging as a viable component of combination treatment plans.
• Combination therapy does not replace CBT-I alone, which remains a first-line, highly effective monotherapy with proven long-term benefits.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41975142/
https://pubmed.ncbi.nlm.nih.gov/41963185/
https://pubmed.ncbi.nlm.nih.gov/41963183/